Principal Financial Group
CLVS

Principal Financial Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Principal Financial Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-103,638
Closed -$123K – 2591
2022
Q3 		$123K Sell
103,638
-151,745
-59% -$237K ﹤0.01% 2295
2022
Q2 		$460K Sell
255,383
-48,308
-16% -$71.3K ﹤0.01% 2076
2022
Q1 		$614K Sell
303,691
-135,738
-31% -$267K ﹤0.01% 2074
2021
Q4 		$1.19M Sell
439,429
-247,275
-36% -$914K ﹤0.01% 1952
2021
Q3 		$3.06M Buy
686,704
+31,942
+5% +$154K ﹤0.01% 1797
2021
Q2 		$3.8M Buy
654,762
+339,453
+108% +$1.99M ﹤0.01% 1782
2021
Q1 		$2.21M Buy
315,309
+18,904
+6% +$127K ﹤0.01% 1837
2020
Q4 		$1.42M Sell
296,405
-162,059
-35% -$820K ﹤0.01% 1868
2020
Q3 		$2.67M Buy
458,464
+202,251
+79% +$1.21M ﹤0.01% 1670
2020
Q2 		$1.73M Buy
+256,213
New +$1.94M ﹤0.01% 1724
2019
Q4 		– Sell
-77,511
Closed -$305K – 2302
2019
Q3 		$305K Sell
77,511
-7,252
-9% -$58.7K ﹤0.01% 2051
2019
Q2 		$1.26M Sell
84,763
-146
-0.2% -$2.64K ﹤0.01% 1809
2019
Q1 		$2.11M Buy
84,909
+5,481
+7% +$137K ﹤0.01% 1731
2018
Q4 		$1.43M Sell
79,428
-9,798
-11% -$200K ﹤0.01% 1765
2018
Q3 		$2.62M Sell
89,226
-1,044
-1% -$40.4K ﹤0.01% 1727
2018
Q2 		$4.11M Buy
90,270
+25,833
+40% +$1.26M ﹤0.01% 1645
2018
Q1 		$3.4M Sell
64,437
-41
-0.1% -$2.39K ﹤0.01% 1661
2017
Q4 		$4.38M Buy
64,478
+17,762
+38% +$1.24M ﹤0.01% 1608
2017
Q3 		$3.85M Sell
46,716
-669
-1% -$53K ﹤0.01% 1628
2017
Q2 		$4.44M Buy
47,385
+40,569
+595% +$2.48M ﹤0.01% 1588
2017
Q1 		$434K Buy
6,816
+918
+16% +$55.8K ﹤0.01% 1939
2016
Q4 		$262K Buy
5,898
+305
+5% +$10.7K ﹤0.01% 2044
2016
Q3 		$202K Buy
+5,593
New +$120K ﹤0.01% 2046
2015
Q4 		– Sell
-54,296
Closed -$4.99M – 2218
2015
Q3 		$4.99M Sell
54,296
-2,179
-4% -$189K 0.01% 1345
2015
Q2 		$4.96M Buy
56,475
+494
+0.9% +$42.3K 0.01% 1411
2015
Q1 		$4.16M Buy
55,981
+351
+0.6% +$24.8K 0.01% 1455
2014
Q4 		$3.12M Sell
55,630
-65
-0.1% -$3.42K ﹤0.01% 1575
2014
Q3 		$2.53M Sell
55,695
-260
-0.5% -$10.9K ﹤0.01% 1600
2014
Q2 		$2.32M Buy
55,955
+134
+0.2% +$6.9K ﹤0.01% 1652
2014
Q1 		$3.87M Buy
55,821
+177
+0.3% +$13K 0.01% 1480
2013
Q4 		$3.35M Buy
55,644
+7,500
+16% +$408K 0.01% 1546
2013
Q3 		$2.93M Buy
48,144
+6,842
+17% +$485K 0.01% 1532
2013
Q2 		$2.77M Buy
+41,302
New +$1.86M 0.01% 1495

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $155M AUM 13% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Principal Financial Group's CLVS Position: Q4 2022 in Review

Principal Financial Group sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 103,638 shares — an estimated $123K sold.

Principal Financial Group first reported a position in CLVS in Q2 2013 and held it in 33 quarters. The position peaked at $4.99M in Q3 2015. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • Principal Financial Group reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • Principal Financial Group sold 103,638 Clovis Oncology, Inc. shares in Q4 2022, an estimated $123K.
  • Principal Financial Group first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 33 quarters.
  • Principal Financial Group's Clovis Oncology, Inc. position peaked at $4.99M in Q3 2015.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on Principal Financial Group's 13F filing for Q4 2022, filed 9 Feb 2023.